Skip to main content
S 3427 117th Congress Senate Health Cancer Cardiovascular and respiratory health Congressional oversight Department of Health and Human Services Digital media Drug safety, medical device, and laboratory regulation Drug, alcohol, tobacco use Emergency medical services and trauma care Executive agency funding and structure Food and Drug Administration (FDA) Government information and archives Government studies and investigations Health care coverage and access Health information and medical records Health programs administration and funding Health technology, devices, supplies Infectious and parasitic diseases Medical research Mental health

Neuroscience Center of Excellence Act of 2021

Introduced: December 16, 2021 Introduced by: Collins, Susan M. Republican · Maine See on congress.gov
Sign in to write a letter Sign in to watch
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Dec 16, 2021
Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S9263-9264)
Dec 16, 2021
Introduced in Senate
 Plain-English summary Congressional Research Service

Neuroscience Center of Excellence Act of 2021

This bill requires the Food and Drug Administration (FDA) to establish the Neuroscience Center of Excellence to address neuroscience diseases and disorders (e.g., addiction, Alzheimer's disease, and psychotic disorders).

The center must carry out various activities, including (1) coordinating with FDA programs that focus on certain areas, such as drug evaluation; (2) convening periodic public meetings to engage with stakeholders to address challenges associated with developing medical products for neuroscience diseases and disorders; (3) establishing a program to facilitate the collection and systemic use of patient experience data to develop such medical products; and (4) convening a public meeting to discuss how to promote equity and the inclusion of traditionally underrepresented populations in the development of such medical products.

The FDA must take actions related to these issues, such as issuing final guidance with recommendations on the collection and use of patient experience data for developing such medical products.

The Government Accountability Office must report to Congress a study that (1) reviews the participation of traditionally underrepresented populations in clinical trials for such medical products, and (2) provides recommendations for improving the participation of these populations.

What's happening now December 16, 2021

Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Sponsor introductory remarks on measure: CR S9263-9264)

 Committees of jurisdiction 1